جستجوی استاد راهنمای دانشگاهی

Shreyas S. Raoمشاهده پروفایل

دانشیار

• Biodegradable Polymers
• Bioengineering
• Biomaterials
• +۱۵ مورد دیگر

Dr. Shreyas S. Rao is an Associate Professor in the Department of Chemical and Biological Engineering at The University of Alabama, College of Engineering. He leads the Rao Laboratory, which is affiliated with the Polymers and Soft Materials Research Center. His research focuses on engineering 3D biomaterial scaffolds to model cancer microenvironments, particularly in metastatic breast cancer and brain metastases. Dr. Rao earned his Ph.D. and M.S. in Chemical Engineering from Ohio State University and a B.E. from R.V. College of Engineering, India. He joined The University of Alabama in 2015 after a postdoctoral position at the University of Michigan. His research interests lie at the intersection of biomaterials, cancer biology, and systems engineering. He develops hydrogel and porous scaffolds to mimic in vivo tissue conditions, enabling the study of tumor dormancy, drug resistance, and metastatic progression in physiologically relevant models. His lab integrates biomaterial design with systems biology to uncover mechanisms of therapeutic resistance and devise strategies to reprogram the tumor microenvironment. The recent publications from his lab highlight a strong focus on metastatic cancer, particularly brain metastasis in breast cancer, tumor dormancy, immune interactions, phage-based therapeutics, and biomimetic modeling. The work spans from fundamental biomaterial design to translational applications in drug screening and personalized medicine. CAREER Award, National Science Foundation, 2018 Grant recipient, Breast Cancer Research Foundation of Alabama, January 2024 Named 'Emerging Leader in Biological Engineering,' Journal of Biological Engineering, 2019 Reichhold-Shumaker Assistant Professorship, The University of Alabama, 2017 Ohio State College of Engineering’s Texnikoi Outstanding Alumni Award, 2024 National Academy of Inventors (NAI) Inductee, 2024 American Cancer Society Research Scholar Award METAvivor Early Career Investigator Award Dr. Rao has successfully advised numerous graduate and undergraduate students, many of whom have received national fellowships and awards. His research is supported by grants from the NSF, American Cancer Society, BCRFA, and METAvivor. He collaborates with researchers at institutions such as the University of Alabama at Birmingham, Ohio State University, and UNC/NCSU. The Rao Lab also engages in outreach, mentoring high school and undergraduate students through programs like Randall Research Scholars and REU. The Rao Laboratory operates within the Science and Engineering Complex and is part of a broader network of research centers including the Polymers and Soft Materials Research Center and the Integrative Center for Athletic and Sport Technology. The lab fosters interdisciplinary collaboration and innovation in bioengineering and cancer therapeutics.

• Molecular Systems Biology
• RNA Processing
• mRNA Metabolism
• +۱۲ مورد دیگر

Bin Tian, Ph.D., is a Professor in the Department of Biochemistry and Biophysics at The Wistar Institute and serves as Program Co-Leader of the Genome Regulation and Cell Signaling Program at the Ellen and Ronald Caplan Cancer Center. He is also the Director of the Center for Systems & Computational Biology. His research integrates molecular biology, computational genomics, and functional studies to understand RNA processing, particularly alternative polyadenylation (APA), and its roles in cancer and immunity. His educational background includes a B.S. in Biochemistry from East China University of Science and Technology and a Ph.D. in Molecular Biology from Rutgers Biomedical and Health Sciences (formerly UMDNJ). He completed postdoctoral training in bioinformatics and genomics at Johnson & Johnson before establishing his independent lab at Rutgers New Jersey Medical School in 2003, where he became a tenured professor in 2014. He joined The Wistar Institute in 2020. His research focuses on molecular systems biology of RNA, including functional genomics of cleavage and polyadenylation, regulation of gene expression through early transcriptional termination, spatial and temporal control of mRNA metabolism via alternative 3’UTRs, and cleavage and polyadenylation inhibition (CPAi) as a cancer therapeutic strategy. His lab has developed key bioinformatics resources like PolyA_DB, APAlyzer, and MAAPER. His recent publications show a strong trend in dissecting APA mechanisms across physiological and pathological contexts, including cancer, neuronal function, and immune cell differentiation. The work combines high-throughput sequencing, single-cell analysis, and computational modeling to uncover how APA regulates mRNA stability, localization, and function. He mentors a team of postdoctoral fellows, predocotoral trainees, and research assistants, contributing to training the next generation of scientists. His lab is actively pursuing novel therapeutics targeting mRNA 3’ end processing in cancer and immune disorders.

Verena Jendrossekمشاهده پروفایل

استاد

• Molecular Cell Biology
• Radiation Biology
• Experimental Radiooncology
• +۷ مورد دیگر

Prof. Dr. Verena Jendrossek is a full Professor and Chair of Cell Biology at the Institute of Cell Biology (Tumor Research), Faculty of Medicine, University of Duisburg-Essen. She also serves as Deputy Managing Director and leads research in molecular and experimental radiooncology. Her group is deeply integrated into the ZMB (Center for Medical Biotechnology) and participates in DFG Research Training Group 1739. Institution: University of Duisburg-Essen School: Faculty of Medicine Department: Institute of Cell Biology (Tumor Research) Leadership: Chair of Cell Biology, Deputy Managing Director Her research focuses on the molecular mechanisms of therapy-induced cell death, tumor resistance, radiation-induced immune changes, and normal tissue toxicity. Her work spans molecular cell biology, radiation biology, and experimental radiooncology , with emphasis on identifying biomarkers and developing novel therapeutic strategies. She investigates the PI3K pathway and microenvironmental influences on treatment response. The recent publications highlight a strong trend in radiation biology, cancer metabolism, autophagy regulation, and immunomodulation post-radiotherapy. Her team explores radiosensitization strategies , metabolic rewiring , and fibrosis mechanisms , often using preclinical models including in vitro , in ovo , and in vivo systems. Collaborative clinical studies in lung cancer are also prominent. Scientific awards are not listed in the provided text. Prof. Jendrossek supervises a large team of doctoral students across medical and scientific disciplines. She leads junior research groups and collaborates with clinical research teams for translational validation of therapeutic approaches. No specific grant information is mentioned, but her involvement in DFG Research Training Group 1739 indicates active funding. She supports a collaborative research environment with structured mentoring. The research group operates within the ZMB and includes junior group leaders such as Dr. Florian Wirsdörfer, PD Dr. Justine Rudner, Dr. Silvia Vega Rubin de Celis, PD Dr. Johann Matschke, and Dr. Farnoush Farahpour. The lab also hosts the Laboratory for Vascular Remodeling led by apl. Prof. Dr. Diana Klein. The team comprises multiple postdocs, doctoral students, and technical staff, indicating a highly active and multidisciplinary research environment.

• Neuro-Oncology
• Early Phase Clinical Trials
• Molecular Biology
• +۳ مورد دیگر

Malaka Ameratunga is a Research Fellow and consultant medical oncologist at Alfred Hospital, serving as Head of Molecular Oncology and Rare Cancers. She holds a PhD submitted in the Shackleton laboratory and has expertise in neuro-oncology and early-phase clinical trials. With 27 peer-reviewed publications, her research focuses on therapeutic approaches in rare brain tumors, biomarker identification, and drug repurposing. She leads multiple clinical trials as Primary Chief Investigator, including studies on novel inhibitors and combination therapies. MBBS and FRACP qualifications Completed a fellowship at the Institute of Cancer Research/Royal Marsden Hospital International collaborations in oncology research Her work contributes to UN SDGs related to health and well-being. She has held editorial roles for journals like Science Advances and mentored interns.

Ingunn Thoمشاهده پروفایل

استاد

• Patient-Centered Drug Formulations
• Pediatric Drug Delivery
• Mucoadhesive Buccal Films
• +۵ مورد دیگر

Ingunn Tho is a Professor at the Department of Pharmacy, University of Oslo. Her research focuses on patient-centered drug formulations, pediatric drug delivery systems, and mucoadhesive buccal films. She leads collaborative projects on nanoparticulate systems and solid dosage forms, emphasizing personalized medicine and compatibility of parenteral drugs. Key research interests include mucosal drug delivery (e.g., vaginal and buccal formulations), nanotechnology applications in drug delivery, and pharmaceutical additive manufacturing. Her work addresses challenges in pediatric care, such as dose adjustment through tablet manipulation and compatibility testing of intravenous drug mixtures. Tho has authored over 100 publications, with recent contributions on drug-polymer solubility prediction, meso-fluidic permeability assessment, and 3D-printed drug formulations. She collaborates with institutions like the Nordic Institute of Dental Materials and Åbo Akademi University. Her projects include the Nordic POP initiative and the Lumiblast research program. Her expertise spans pharmaceutical formulation design, quality-by-design principles, and in vitro evaluation methods. She is actively involved in the Controlled Release Society (CRS) Nordic Chapter and contributes to guidelines for parenteral nutrition compatibility testing.

• Mycology
• Molecular Biology
• Genomics
• +۶ مورد دیگر

Joseph Strauss is a Full Professor at the University of Natural Resources and Life Sciences Vienna (BOKU), leading the Institute of Microbial Genetics. With a career spanning over three decades, he has focused on fungal genetics, epigenetics, and bioactive metabolite discovery, particularly in filamentous fungi and pathogens. His work bridges fundamental research with applications in agriculture, medicine, and environmental biotechnology. Research Focus: Epigenetic regulation of fungal secondary metabolism, chromatin dynamics, bioactive compounds, nitrate signaling, and microbial interactions. Projects: Leads multiple grants from Austrian Science Fund (FWF), European Commission, and industry partners, including studies on chromatin engineering, fungal biotechnology, and toxin biosynthesis. His recent publications highlight advancements in chromatin proteomics, fungal pathogenicity, and novel bioactive molecules like luteapyrone and rasfonin. Articles emphasize broad disciplines such as Fungal Genetics, Epigenetics, and Natural Product Discovery, with subfields including secondary metabolite clusters, histone modifications, and stress response mechanisms. Scientific Awards: 2021 - Keratinophyton straussii fungal species named after him 1999 - START Preis 1995 - EMBO Stipendium 1994 - OTTO LOEWI Stipendium He has supervised over 69 theses and contributed to 186 publications, reflecting his leadership in fungal genomics and its applications. Projects like 'Bioaktive Mikrobielle Metaboliten' and 'TASSMATA' underscore his commitment to translating research into sustainable solutions.

Denise Rooneyمشاهده پروفایل

استاد

• Materials Chemistry
• Metal Complexes
• Antimicrobial Agents
• +۵ مورد دیگر

Professor Denise Rooney serves as Head of the Department of Chemistry and Associate Dean of the Faculty of Science and Engineering at Maynooth University, currently on sabbatical. She has been a prominent figure at the university since 1994, contributing significantly to both academic leadership and research initiatives. Her administrative roles include serving as Project Lead for the Virtual Laboratories in Higher Education HCI Pillar 3 project. PhD in Chemistry from Queen's University Belfast Post-doctoral research at the University of York Professor Rooney's research centers on Metal Complexes and Materials Chemistry, with particular emphasis on antimicrobial metal complexes, polymer chemistry, and hydrogel technology. Her work bridges fundamental chemistry with practical applications in environmental science and biomedicine. She has made significant contributions to the development of novel phenanthroline-based ligands and their metal complexes for antibacterial applications, as well as creating innovative hydrogel systems for controlled release of agricultural inhibitors. Analysis of her recent publications reveals a strong research trajectory combining traditional inorganic chemistry with modern materials science approaches. Her work demonstrates consistent focus on developing functional materials with applications ranging from antimicrobial agents to environmental protection technologies. The interdisciplinary nature of her research connects chemistry with biology, materials science, and environmental engineering. As Head of the Department of Chemistry, Professor Rooney oversees academic programs and research activities while maintaining an active research laboratory. Her leadership extends to the Faculty level as Associate Dean, where she contributes to strategic planning and academic development across the Faculty of Science & Engineering.

Diana S-L. Chowمشاهده پروفایل

استاد

• Translational Drug Development
• Oncology
• Pharmacokinetics
• +۳ مورد دیگر

Diana S-L. Chow is a Professor in the Department of Pharmacological and Pharmaceutical Sciences at the University of Houston College of Pharmacy . She also holds the Paula & John J. Lovoi Sr. Endowed Professor in Drug Discovery and Development and serves as Director of the Institute of Drug Education and Research . B.S. in Pharmacy, National Taiwan University, School of Pharmacy M.S. in Natural Product Chemistry, Ohio State University Ph.D. in Pharmaceutics, University of British Columbia Dr. Chow's research spans 40 years of translational drug development with a focus on anti-cancer therapies . She has pioneered formulations resulting in FDA-approved products like Busulfex® , with ongoing work on lung, pancreatic, and prostate cancer treatments. Her recent studies expand to underrepresented minority (URM) populations , pediatrics, and neurologically injured patients, emphasizing pharmacokinetics/pharmacodynamics (PK/PD) optimization. Her publications highlight expertise in analytical method development (e.g., LC-MS/MS assays), nanoparticle-based drug delivery , and neuroprotective agents . Key themes include preclinical-to-clinical translation , metabolite quantification , and bioavailability enhancement . 2023 Meritorious Achievement Award, UH College of Pharmacy 2023 Pharmaceutical Sciences Alumni Agent of Change, University of British Columbia 2016 Fellow, National Academy of Inventors 2009 Inventor of the Year, HIPLA Dr. Chow mentors extensively, with recognition as Outstanding Graduate Mentor (2022, 2021), and contributes to graduate education and research infrastructure through her directorship.

Jennifer Cocohobaمشاهده پروفایل

استاد

• HIV/AIDS
• Pharmacy Practice
• Medication Adherence
• +۳ مورد دیگر

Jennifer Cocohoba is a Professor in the Department of Clinical Pharmacy at the University of California San Francisco (UCSF) School of Pharmacy , where she holds the McKesson Professorship of Pharmaceutical Technology . As Vice Chair of Faculty Development , she mentors early-career faculty and promotes professional development opportunities. Her dual role as Clinical Pharmacist at the Women’s HIV Program focuses on optimizing antiretroviral therapy, adherence strategies, and opioid stewardship. Education: PharmD (2001, UCSF) MAS in Clinical Research (2008, UCSF) Certificate in Implementation Sciences (2012, UCSF) Certificate in Geographic Information Sciences (2013, Cal Poly Pomona) HIV Expert certification (2008, American Academy of HIV Medicine) Her research spans HIV treatment and prevention , with emphasis on medication adherence , health disparities , pharmacoepidemiology , and implementation science . She investigates sex-related disparities in HIV care, Filipina-American health behaviors, and pharmacy-based interventions for chronic disease management. Recent studies focus on integrase inhibitor-related weight gain , long-acting injectable therapies , and telemedicine for alcohol use disorders . Scientific recognition includes: Fellow of the California Society of Health-System Pharmacists (2012) Endowed chair appointments at UCSF (2022) Honors from the UCSF Academy of Medical Educators (2021) She actively contributes to pharmacy education reform and policy analysis , including work on expanding pharmacist prescribing authority for HIV pre-exposure prophylaxis (PrEP) . Her community engagement with Mabuhay Health Center and research in pharmacist-patient communication reflect her commitment to equitable healthcare delivery.

• Cancer Drug Development
• Translational Research
• Pre-clinical Studies
• +۵ مورد دیگر

Rena S. Lapidus, PhD is an Associate Professor in the Department of Medicine at the University of Maryland School of Medicine. She serves as the Director of the Translational Laboratory Shared Service (TLSS) at the University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC), where she also holds the positions of Project Coordinator of the Translational Working Group and Assistant Director of the UMGCCC Shared Services. With over 23 years of experience spanning both industry and academia, Dr. Lapidus brings extensive expertise in cancer drug development and translational research. Dr. Lapidus earned her Bachelor of Arts in Chemistry from Boston University, followed by a PhD in Pharmacology from the University of Maryland School of Medicine. She completed her postdoctoral training at The Johns Hopkins Oncology Center. Her career includes 12 years in the pharmaceutical industry working on small molecule drug development, followed by 11 years leading the TLSS at UMGCCC. Dr. Lapidus's research focuses on translating novel drugs from bench to bedside through comprehensive preclinical testing. Her laboratory specializes in cancer drug development , particularly for acute myeloid leukemia (AML), with expertise in translational research , pre-clinical studies , and in vivo cancer models . The TLSS under her direction conducts both in vitro studies (proliferation and cell death assays, IC50 generation, apoptotic assays, Western analysis) and in vivo studies (maximum tolerated dose studies, pharmacokinetic studies, cancer efficacy and pharmacodynamic studies). The laboratory has developed numerous novel flank, orthotopic and primary xenograft models to test novel compounds in cancer and possesses an umbrella Animal Use protocol approved for oncology studies. Analysis of Dr. Lapidus's recent publications (2023-2025) reveals a strong focus on innovative therapeutic approaches for acute myeloid leukemia, particularly exploring combinations of pegcrisantaspase with venetoclax and other agents to overcome drug resistance. Her work also extends to pancreatic cancer, head and neck squamous cell carcinoma, and breast cancer, with particular emphasis on metabolic targeting, epigenetic therapies, and biomarker development for treatment response prediction. A notable trend is her investigation of amino acid metabolism (particularly glutamine) as a therapeutic target in hematologic malignancies. Dr. Lapidus has extensive experience mentoring researchers and collaborating on translational projects. Her laboratory serves as a critical resource for UMGCCC investigators seeking preclinical data to support grant applications and clinical trial development. The TLSS provides essential services including in vitro and in vivo testing of novel compounds, pharmacokinetic studies, and development of specialized cancer models. The Translational Laboratory Shared Service under Dr. Lapidus's direction is equipped with the necessary tools to generate in vivo oncology data for preclinical investigators. The laboratory has particular expertise in developing and utilizing various xenograft models to test novel cancer therapeutics. Dr. Lapidus's unique background bridging industry drug development and academic research enables her to effectively translate scientific discoveries into clinically relevant applications.

Chung-Tsen Hsuehمشاهده پروفایل

استاد

• Medical Oncology
• Hematology
• Targeted Therapy
• +۶ مورد دیگر

Chung-Tsen Hsueh, MD, PhD is a Professor in the Hematology and Oncology Division at . With a dual background in clinical medicine and research, his work bridges medical oncology, radiation oncology, and molecular biology. Education: MD from Taipei Medical University (1986), PhD from SUNY University at Buffalo (1993) Research Focus: Specializing in targeted therapy , immunotherapy , and biomarker-driven treatments , Hsueh has led or participated in 69 peer-reviewed publications. His research spans gastrointestinal cancers (gastric, pancreatic, colorectal), non-small cell lung cancer , and rare tumors like desmoid tumors and angiosarcomas. Key Trends: Recent publications emphasize immunotherapy combinations (anti-CTLA-4 + anti-PD-1), proton therapy applications in metastatic settings, and genomic biomarker integration for precision oncology. His work addresses drug resistance mechanisms (e.g., KRAS/BRAF mutations) and novel toxicity management (e.g., nivolumab-induced pericardial effusion). Grants & Leadership: Hsueh has served as Principal Investigator (PI) or Co-Investigator in over 20 clinical trials sponsored by entities like National Cancer Institute , Amgen , and SWOG . Notable trials include CodeBreak 101 (KRAS inhibition) and DART S1609 (immunotherapy for rare tumors).

Tülay Kuşمشاهده پروفایل

استاد

• Medical Oncology
• Immunotherapy
• Molecular Targeted Therapies
• +۷ مورد دیگر

Professor Tülay Kuş is a distinguished faculty member at Gaziantep University Faculty of Medicine, Department of Internal Medicine, specializing in Medical Oncology. She currently holds the position of Professor after previously serving as Associate Professor since 2020. Her extensive academic and clinical career spans multiple prestigious institutions including Gaziantep University, Adıyaman University, and Dr. Ersin Arslan Education and Research Hospital. Dr. Kuş completed her medical education at Kocaeli University Faculty of Medicine (1999-2006), followed by medical specialization at Gaziantep University Faculty of Medicine, Department of Internal Medicine (2006-2011 and 2013-2016). Her educational background reflects a strong foundation in internal medicine with specialized focus on oncology. Her research interests span multiple areas of oncology including immunotherapy, molecular targeted therapies, breast cancer, lung cancer, gastrointestinal tumors, gynecological oncology, and radioligand therapy. Dr. Kuş has made significant contributions to the field through her extensive publication record and book chapters on cutting-edge cancer treatments. Analysis of her 15 most recent publications (2022-2024) reveals a strong focus on precision oncology approaches, including molecular biomarkers (KRAS, STK11, KEAP1), advanced imaging techniques (FAPI PET/CT), radioligand therapies (PSMA-targeted), and critical evaluation of clinical trial methodologies. Her work demonstrates expertise across multiple cancer types with particular emphasis on breast, lung, prostate, and gastrointestinal cancers. Scientific Awards 2016 Mesleki Dernekler en iyi sözel bildiri ödülü - Anatolian Medical Oncology Association 2015 Professional Associations Best Oral Presentation - Anatolian Medical Oncology Association Dr. Kuş has successfully supervised multiple graduate students, with completed theses focusing on nivolumab efficacy in lung cancer, imatinib treatment in gastrointestinal stromal tumors, and genetic testing perspectives in breast and ovarian cancer. Her extensive professional development includes participation in numerous national and international oncology courses covering head and neck cancers, hematological malignancies, thoracic oncology, neuroendocrine tumors, and colorectal cancer through institutions including the University of Oxford. She maintains active membership in the Turkish Medical Oncology Association and has contributed significantly to the field through her research, teaching, and clinical practice in medical oncology.

• Medical Education
• Palliative Medicine
• Curriculum Mapping
• +۷ مورد دیگر

Professor Faye Gishen serves as Professor of Medical Education and Palliative Medicine, Director of UCL Medical School, and Head of the MBBS Programme at University College London. With medical qualifications including MBBS (1997), MRCP (2000), FRCP (2014), and EdD, she bridges clinical practice with academic medicine while maintaining an honorary consultant contract at the Royal Free London. Her research spans two interconnected domains: clinical palliative care through collaborations with the Francis Crick Institute on tumor heterogeneity, and medical education innovation focused on curriculum mapping, student resilience, and diversifying medical education. She pioneered UCL's electronic curriculum map which has improved student assessment experiences, and her work on Schwartz Rounds for medical students has informed national practice and enhanced reflection and wellbeing. Her research portfolio demonstrates a consistent focus on improving medical education through evidence-based innovation. Professor Gishen has received numerous awards recognizing her educational leadership, including multiple UCL Provost Awards, Excellence in Medical Education Awards, and was shortlisted for the Royal College of Physicians Excellence in Patient Care Award. She has organized national symposia on medical student resilience attended by 28 of 41 UK medical schools and contributes to curriculum reviews at institutions worldwide including St George's University, King's College London, and international institutions in Singapore, Jordan, and Egypt. UCL Provost Award (2020) UCL Faculty Award UCL Excellence in Medical Education Award (EMEA) UCL Provost Education Award Shortlisted for Royal College of Physicians Excellence in Patient Care Awards (2019) Inaugural Provost Team Award for Embedding Equality, Diversity and Inclusion (2020) As an educator, Professor Gishen has transformed medical education through innovative modules on Sustainability & Climate Change in Healthcare, Doctor as Data Scientist, and Patient Safety. She has supervised numerous postgraduate students and nurtured early career researchers. Her leadership extends nationally as she sits on the Medical Schools Council Executive, the national body for UK medical schools, shaping medical education policy across the country.

• Fetal Physiology
• Placental Development
• Developmental Origins of Health and Disease
• +۵ مورد دیگر

Professor Janna Morrison is a Professor of Physiology at the University of South Australia within the Clinical & Health Sciences school. She is based at the City West Campus (HB5-28) and serves as a Research Degree Supervisor. Her research primarily focuses on fetal physiology and developmental origins of health and disease, with particular emphasis on placental function, cardiovascular development, and respiratory systems in animal models. Dr. Morrison's research interests span fetal physiology, placental development, developmental origins of health and disease, cardiovascular development, respiratory development, and pregnancy complications. Her work frequently utilizes sheep models to investigate how maternal conditions affect fetal development and how these developmental changes may program health outcomes later in life. She has made significant contributions to understanding intrauterine growth restriction, fetal cardiac development, and the pulmonary surfactant system. Analysis of her recent publications reveals a strong focus on using advanced imaging techniques like MRI to assess maternal-fetal physiology, investigating sex-specific responses to developmental challenges, and exploring interventions that might mitigate adverse programming effects. Her research bridges basic science with potential clinical applications in perinatal medicine. Professor Morrison has received funding from major Australian research councils including ARC and NHMRC grants (DP190102263, DP220103289, 511340). She leads the Early Origins of Adult Health Research Group within the Health and Biomedical Innovation division at UniSA. Her laboratory work frequently involves collaborations with the South Australian Health and Medical Research Institute (SAHMRI) and utilizes sophisticated techniques including cardiac MRI feature tracking, redox monitoring systems, and molecular analysis of tissue samples from animal models.

• Analytical Chemistry
• Mass Spectrometry
• Biomaterials
• +۱۲ مورد دیگر

Lisa Elviri is an Associate Professor in Analytical Chemistry at the Department of Pharmacy, University of Parma, Faculty of Sciences. She holds a PhD in Chemical Sciences (Analytical Chemistry) from the University of Parma and has been a tenured researcher since 2004. Education: PhD in Chemical Sciences (Analytical Chemistry, University of Parma); Laurea in Chemistry (University of Parma). Her research spans analytical chemistry , mass spectrometry , biomaterials , 3D printing , and clinical diagnostics . She focuses on developing LC-MS and immunoenzymatic methods, validating techniques for pharmaceutical analysis, and designing chitosan-based scaffolds for tissue regeneration. Recent publications highlight work on Alzheimer’s disease (PCSK9 inhibition, APOE4 genotype studies), 3D-printed medical devices , and biorefinery quality monitoring using spectroscopy. Her teaching includes Analytical Chemistry for 5-year Master’s programs in Pharmacy and Pharmaceutical Chemistry. She has authored 75 international publications, 140 conference communications, and holds an H-index of 26 (Google Scholar). Her office is located at the Science and Technology Campus, Parma.